Cardiovascular magnetic resonance signs of ischemia in hypertrophic cardiomyopathy

International Journal of Cardiology

Volumn 128, Issue 3, 2008, Pages 364-373

  Melacini, Paola ^a   Corbetti, Francesco ^a   Calore, Chiara ^a   Pescatore, Valentina ^a   Smaniotto, Gessica ^b   Pavei, Andrea ^a   Bobbo, Fabiana ^a   Cacciavillani, Luisa ^a   Iliceto, Sabino ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Hypertrophic cardiomyopathy; Magnetic resonance imaging; Myocardial ischemia

Indexed keywords

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; EDEMA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE WALL; HEART PERFUSION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; ST SEGMENT DEPRESSION; THORAX PAIN;

ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA;

EID: 48149115363     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.06.023     Document Type: Article

References (52)

1. Richardson P., McKenna W.J., Bristow M., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93 (1996) 841-842
2. Maron B.J., McKenna W.J., Danielson G.K., et al. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy). J Am Coll Cardiol 42 (2003) 1687-1713
3. Olivotto I., Cecchi F., Gistri R., et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 47 (2006) 1043-1048
4. Varnava A.M., Elliott P.M., Sharma S., McKenna W.J., and Davies M.J. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 84 (2000) 476-482
5. Varnava A.M., Elliott P.M., Mahon N., Davies M.J., and McKenna W.J. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol 88 (2001) 275-279
6. Kim R.J., Fieno D.S., Parrish T.B., et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100 (1999) 1992-2002
7. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343 (2000) 1445-1453
8. Wu E., Judd R.M., Vargas J.D., Klocke F.J., Bonow R.O., and Kim R.J. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 357 (2001) 21-28
9. Weinmann H.J., Brasch R.C., Press W.R., and Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol 142 (1984) 619-624
10. Kim R.J., Choi K.M., and Judd R.M. Assessment of myocardial viability by contrast enhancement. In: Higgins C.B., and de Roos A. (Eds). Cardiovascular MRI and MRA (2003), Lippincott Williams and Wilkins, Philadelphia, PA 209-237
11. Kim R.J., Chen E.L., Lima J.A., and Judd R.M. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation 94 (1996) 3318-3326
12. Flacke S.J., Fischer S.E., and Lorenz C.H. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology 218 (2001) 703-710
13. Rehwald W.G., Fieno D.S., Chen E.L., Kim R.J., and Judd R.M. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 105 (2002) 224-229
14. Dumont C.A., Monserrat L., Soler R., et al. Interpretation of electrocardiographic abnormalities in hypertrophic cardiomyopathy with cardiac magnetic resonance. Eur Heart J 27 (2006) 1725-1731
15. Choudhury L., Mahrholdt H., Wagner A., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40 (2002) 2156-2164
16. Moon J.C., McKenna W.J., McCrohon J.A., Elliott P.M., Smith G.C., and Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41 (2003) 1561-1567
17. Moon J.C., Mogensen J., Elliott P.M., et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 91 (2005) 1036-1040
18. Harris K.M., Spirito P., Maron M.S., et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 114 (2006) 216-225
19. Moon J.C., Reed E., Sheppard M.N., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43 (2004) 2260-2264
20. Papavassiliu T., Schnabel P., Schroder M., and Borggrefe M. CMR scarring in a patient with hypertrophic cardiomyopathy correlates well with histological findings of fibrosis. Eur Heart J 26 (2005) 2395
21. Knaapen P., van Dockum W.G., Bondarenko O., et al. Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: comparison between cardiac MRI and PET. J Nucl Med 46 (2005) 923-929
22. Basso C., Thiene G., Corrado D., Buja G., Melacini P., and Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 31 (2000) 988-998
23. Cecchi F., Olivotto I., Gistri R., Lorenzoni R., Chiriatti G., and Camici P.G. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349 (2003) 1027-1035
24. Spirito P., Bellone P., Harris K.M., Bernabo P., Bruzzi P., and Maron B.J. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 1778-1785
25. Blackburn H. Classification of the electrocardiogram for population studies: Minnesota Code. J Electrocardiol 2 (1969) 305-310
26. Tarantini G., Cacciavillani L., Corbetti F., et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol 46 (2005) 1229-1235
27. Abdel-Aty H., Boyè P., Zagrosek A., et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis, comparison of different approaches. J Am Coll Cardiol 45 (2005) 1815-1822
28. Finn J.P., and Simonetti O.P. Pulse sequence design in MRI. In: Edelman R.R., Zlatkin M.B., and Hesselink J.R. (Eds). Clinical magnetic resonance imaging. 2nd Edition (1996), Saunders 145-176
29. Cerqueira M.D., Weissman N.J., Dilsizian V., et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105 (2002) 539-542
30. Arai A.E. Magnetic resonance first pass perfusion imaging. Top Magn Reson Imaging 11 (2000) 383-398
31. Taylor A.J., Al-Saadi N., Abdel-Haty H., Schultz-Menger J., Messroghli D.R., and Friedrich M.G. Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging. Circulation 109 (2004) 2080-2085
32. Simonetti O.P., Kim R.J., Fieno D.S., et al. An improved MRI technique for the visualization of myocardial infarction. Radiology 218 (2001) 215-223
33. Spirito P., and Bellone P. Natural history of hypertrophic cardiomyopathy. Br Heart J 72 (1994) S10-S12
34. Rickers C., Wilke N.M., Jerosch-Herold M., et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 112 (2005) 855-861
35. Nagueh S.F., and Mahmarian J.J. Noninvasive cardiac imaging in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 48 (2006) 2410-2422
36. Consevage M.W., Salada G.C., Baylen B.G., Ladda R.L., and Rogan P.K. A new missense mutation, Arg719Gln, in the beta-cardiac heavy chain myosin gene of patients with familial hypertrophic cardiomyopathy. Hum Mol Genet 3 (1994) 1025-1026
37. Huang X., Song L., Ma A.Q., et al. A malignant phenotype of hypertrophic cardiomyopathy caused by Arg719Gln cardiac beta-myosin heavy-chain mutation in a Chinese family. Clin Chim Acta 310 (2001) 131-139
38. Van Driest S.L., Ackerman M.J., Ommen S.R., et al. Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation 106 (2002) 3085-3090
39. Garcia-Dorado D., and Oliveras J. Myocardial oedema: a preventable cause of reperfusion injury?. Cardiovasc Res 27 (1993) 1555-1563
40. Garcia-Dorado D., Oliveras J., Gili J., et al. Analysis of myocardial oedema by magnetic resonance imaging early after coronary artery occlusion with or without reperfusion. Cardiovasc Res 27 (1993) 1462-1469
41. Miller S., Schick F., Scheule A.M., et al. Conventional high resolution versus fast T2-weighted MR imaging of the heart: assessment of reperfusion induced myocardial injury in an animal model. Magn Reson Imaging 18 (2000) 1069-1077
42. Nilsson J.C., Nielsen G., Groenning B.A., et al. Sustained postinfarction myocardial oedema in humans visualised by magnetic resonance imaging. Heart 85 (2001) 639-642
43. Willerson J.T., Scales F., Mukherjee A., et al. Abnormal myocardial fluid retention as an early manifestation of ischemic injury. Am J Pathol 87 (1977) 159-188
44. Abdel-Aty H., Zagrosek A., Schltz-Menger J., et al. Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation 109 (2004) 2411-2416
45. Aso H., Takeda K., Ito T., Shiraishi T., Matsumura K., and Nakagawa T. Assessment of myocardial fibrosis in cardiomyopathic hamsters with gadolinium-DTPA enhanced magnetic resonance imaging. Invest Radiol 33 (1998) 22-32
46. Wigle E.D., Rakowski H., Kimball B.P., and Williams W.G. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 92 (1995) 1680-1692
47. Cannon III R.O., Rosing D.R., Maron B.J., et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy. Circulation 71 (1985) 234-243
48. Krams R., Kofflard M.J., Duncker DJ., et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 97 (1998) 230-233
49. Nienaber C.A., Gambhir S.S., Mody F.V., et al. Regional myocardial blood flow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy. Circulation 87 (1993) 1580-1590
50. Camici P., Chiriatti G., Lorenzoni R., et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 17 (1991) 879-886
51. Sipola P., Lauerma K., Husso-Saastamoinen M., et al. First-Pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn Mutation of the αTropomyosin gene. Radiology 226 (2003) 129-137
52. Petersen S.E., Jerosch-Herold M., Hudsmith L.E., et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 115 (2007) 2418-2425